Persistence has paid off for Abeona Therapeutics and its gene therapy for recessive dystrophic epidermolysis bullosa (RDEB).

(NASDAQ:ABEO) announced that the U.S. Food and Drug Administration (FDA) has approved Zevaskyn (prademagene zamikeracel) for the treatment of wounds in adults and children with recessive dystrophic ...

Cleveland-based Abeona Therapeutics Inc. (Nasdaq: ABEO) announced Tuesday, April 29, that it has received U.S. Food and Drug ...

We are a system of 8 drug & alcohol treatment centers that help both adolescents ... Insurances and Payment We are in network with nearly all commercial providers in the PA, DE, MD, NJ, NY ...